Actuate Therapeutics (NASDAQ:ACTU) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Actuate Therapeutics (NASDAQ:ACTU) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Actuate Therapeutics in a report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Price Performance

Actuate Therapeutics stock opened at $4.33 on Friday. The firm has a 50 day simple moving average of $5.85 and a 200-day simple moving average of $6.76. The stock has a market cap of $100.64 million, a price-to-earnings ratio of -4.98 and a beta of -0.16. Actuate Therapeutics has a 1-year low of $4.04 and a 1-year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02.

Insider Activity

In related news, Director Todd S. Thomson sold 280,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 904,795 shares in the company, valued at $5,247,811. This trade represents a 23.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 69.34% of the company’s stock.

Institutional Trading of Actuate Therapeutics

Hedge funds have recently made changes to their positions in the business. ABS Direct Equity Fund LLC purchased a new position in shares of Actuate Therapeutics in the fourth quarter valued at approximately $40,000. Deutsche Bank AG lifted its holdings in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after buying an additional 8,051 shares in the last quarter. Sfmg LLC boosted its position in Actuate Therapeutics by 32.3% in the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after buying an additional 3,550 shares during the period. Bank of America Corp DE grew its stake in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after acquiring an additional 15,267 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Actuate Therapeutics during the fourth quarter worth $102,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.